A detailed history of Royal Bank Of Canada transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 11,850 shares of AMLX stock, worth $41,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,850
Previous 17,131 30.83%
Holding current value
$41,593
Previous $32,000 18.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.65 - $3.24 $8,713 - $17,110
-5,281 Reduced 30.83%
11,850 $38,000
Q2 2024

Aug 14, 2024

BUY
$1.62 - $2.71 $25,561 - $42,761
15,779 Added 1167.09%
17,131 $32,000
Q1 2024

Nov 05, 2024

SELL
$2.71 - $19.57 $42,761 - $308,795
-15,779 Reduced 92.11%
1,352 $3,000
Q1 2024

May 15, 2024

SELL
$2.71 - $19.57 $40,116 - $289,694
-14,803 Reduced 91.63%
1,352 $3,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $97,284 - $148,787
8,060 Added 99.57%
16,155 $237,000
Q3 2023

Nov 14, 2023

BUY
$18.08 - $23.45 $72,699 - $94,292
4,021 Added 98.7%
8,095 $148,000
Q2 2023

Aug 14, 2023

BUY
$20.98 - $31.42 $9,357 - $14,013
446 Added 12.29%
4,074 $87,000
Q1 2023

May 15, 2023

SELL
$27.71 - $40.93 $84,487 - $124,795
-3,049 Reduced 45.66%
3,628 $106,000
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $157,794 - $208,235
5,304 Added 386.31%
6,677 $246,000
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $6,259 - $11,285
365 Added 36.21%
1,373 $38,000
Q2 2022

Aug 15, 2022

SELL
$6.85 - $19.93 $22,509 - $65,489
-3,286 Reduced 76.53%
1,008 $19,000
Q1 2022

May 16, 2022

BUY
$12.85 - $32.9 $55,177 - $141,272
4,294 New
4,294 $56,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $205M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.